Investors Urged to Join Class Action Against Altimmune, Inc. Amid Securities Fraud Claims

Investor Alert: Class Action Against Altimmune, Inc.

Pomerantz LLP, a prominent law firm specializing in class action lawsuits, has announced the filing of a significant class action against Altimmune, Inc. (NASDAQ: ALT). This lawsuit stems from allegations that Altimmune and some of its key officers may have engaged in securities fraud and other unlawful business practices impacting investors negatively.

Background of the Case

The class action addresses potential misconduct that occurred in relation to the company's stock performance. It specifically invites investors who have experienced financial losses linked to their investments in Altimmune shares to contact Pomerantz LLP for further involvement in the class. Investors are urged to act promptly as the deadline to apply for Lead Plaintiff status in the case is approaching on October 6, 2025.

Recent Developments

On June 26, 2025, Altimmune released a press statement detailing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, aimed at treating metabolic dysfunction associated with nonalcoholic fatty liver disease (MASH). The trial results indicated significant issues; while a positive trend improved in fibrosis reduction, the necessary statistical significance was not achieved due to an unexpectedly high placebo response. This disappointment has raised critical concerns regarding the company’s management and transparency in communicating the trial's expectations versus reality.

The result of this announcement was dramatic, as Altimmune’s stock price plummeted by $4.10 per share, marking a staggering 53.2% decline to close at $3.61. This sharp fall sparked further scrutiny of the company’s integrity and led to heightened concerns among investors about the overall management of Altimmune.

Call to Action

Investors who acquired Altimmune shares during the outlined class period and have incurred losses are encouraged to reach out to Danielle Peyton from Pomerantz LLP. Contact can be made either via email at [email protected] or through the firm’s toll-free number (888) 4-POMLAW, ext. 7980. Providing details such as a mailing address, phone contact, and number of shares purchased will facilitate the process for those looking to participate in the class action.

About Pomerantz LLP

Established by the late Abraham L. Pomerantz, who is hailed as a pioneer in the realm of class action litigation, Pomerantz LLP has a rich history spanning over 85 years. The firm is widely recognized for its efforts to protect the rights of investors and has successfully secured numerous multi-million dollar settlements in securities fraud cases. The firm maintains offices in major cities including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, and continues to strive for justice on behalf of those affected by corporate misconduct.

For those affected by the downturn in Altimmune's stock value, this class action presents a formidable opportunity to seek recompense for losses incurred. The deadline moves closer, and affected investors are encouraged not to delay in seeking legal representation and participating in the lawsuit.